Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.40 |
| ▸ | KLK1 | P06870 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6842615 | 0.87 | MMP13 (0.51) | MMP13NR1H4EPHX2HDAC1KLKB1 | |
| SCHEMBL6196444 | 0.87 | MMP13 (0.54) | MMP13NR1H4EPHX2HDAC1KLKB1 | |
| SCHEMBL6194845 | 0.85 | MMP13 (0.48) | MMP13NR1H4EPHX2HDAC1KLKB1 | |
| SCHEMBL6838118 | 0.84 | MMP13 (0.55) | MMP13NR1H4EPHX2HDAC1 | |
| SCHEMBL6843392 | 0.84 | NR1H4 (0.52) | MMP13NR1H4EPHX2 | |
| SCHEMBL6843390 | 0.84 | MMP13 (0.40) | MMP13 | |
| SCHEMBL6194250 | 0.84 | NR1H4 (0.52) | MMP13NR1H4EPHX2HDAC1KLKB1 | |
| SCHEMBL6842501 | 0.83 | NR1H4 (0.54) | MMP13NR1H4EPHX2 | |
| SCHEMBL6843263 | 0.83 | MMP13 (0.67) | MMP13NR1H4 | |
| SCHEMBL6176003 | 0.81 | MMP13 (0.65) | MMP13NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | MMP13 3/4885NR1H4 1615/4885EPHX2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.